DEENOVA
11.7.2022 06:02:14 CEST | Business Wire | Press release
Following its previous announcements in March 2022, for the release of three new innovative additions to its award winning D3 product line of mechatronic solutions, Deenova further consolidates its technological leadership in the field of pharmacy automation, and announced today the unveiling of the second generation of its ALL-IN-1 robot, able to automatically repack in unit dose, all medication forms: oral solids and liquids such as ampoules, syringes, vials and all types of patches sachet and suppositories.
The ultimate generation of this innovative fully automated repackaging robot has been designed to ensure the efficiency and unmatched fluency of its predecessor, while improving versatility and reliability with optimized movements of the robotic arm.
With the operator in mind, and for an unrivaled customer experience, particular attention has been put in the functional aspects of the technology such as improving the vision system with new AI functionalities, lowering the overall noise level, improving the ergonomics and developing a smooth and intuitive user interface, perfectly in line with Deenova ’s vision of “sensitive robotics ”: a technology in contact with the human side in a reliable support relationship anytime, anywhere.
Fulvio Rudello , Chief Operation Officer at Deenova , declared: “I am very excited to see that our new ALL-IN-1 robot has successfully passed all the factory validation tests, and is now fully operational in Deenova ’s central unit dose laboratory near Piacenza, serving 22 hospitals sites in Italy, with more than 6 millions unit doses produced per year. This is the first step of a wider upgrading process of our facility and will be followed by the gradual replacement of existing equipment starting with implementation during the first quarter of 2023, of the new D3 AIDE Cut , Deenova 's latest modular mechatronic solutions for the repackaging of oral solid medications in unit doses.”
“Our 100% customer retention rate in Italy, after more that 15 years of operations” explained Christophe Jaffuel , Chief Commercial Officer at Deenova “motivates us to relentlessly define new standards of performance and customer experience. Having this new ALL-IN-1 robot, fully operating in our facilities is a great premise for our upcoming breakthrough installations in UK and Germany”
Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry. Deenova ’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220710005007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery13.7.2026 08:16:00 CEST | Press release
Claude and Claude Code embedded into LTM BlueVerse™ AI Delivery Fabric to power AI-led transformations LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows. LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains. The three strategic focus areas of partnership include:LTM BlueVerse™: AI Delivery Fabric LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into del
Sofinnova Partners Appoints David Evans as Partner13.7.2026 08:00:00 CEST | Press release
Sofinnova strengthens its growth strategy with a high-caliber London-based Partner:Physician-scientist combining frontline clinical experience, health financing and policy expertise, and a proven track record in venture capitalOver 20 years in drug development at Bristol Myers Squibb, Eli Lilly, and the Roche Venture Fund as well as in healthcare policy and financing Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products13.7.2026 01:00:00 CEST | Press release
Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi-Phased InitiativeTakeda Will Initially Invest up to 30 Million U.S. Dollars to Begin the Establishment of an Ecosystem for Plasma-Derived Medicinal Products, including a pilot of a National Plasma Donation NetworkCollaboration Builds on Decades-Long Relationship Between Takeda and Indonesia Focused on Elevating Healthcare Standards for Patients Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia’s plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a fractionation license granted to Takeda by the Ministry of Health (MoH),
The Rock-It Company Expands to Abu Dhabi, Strengthening the Capital’s Position as a Global Hub for Luxury, Culture, and Major Events11.7.2026 18:12:00 CEST | Press release
The Rock-It Company (Rock-It), one of the world’s leading providers of specialist logistics for time-critical and high-value sectors across live events and luxury goods, has expanded its footprint in the UAE to Abu Dhabi, in partnership with the Abu Dhabi Investment Office (ADIO). The expansion in the region brings Rock-It’s portfolio of renowned brands to the UAE capital to support Abu Dhabi’s vision of becoming a world-leading destination for luxury experiences, cultural attractions, and global events, while reinforcing the emirate’s position as a regional re-export hub and advanced logistics base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260710305177/en/ Through the collaboration, Rock-It seeks to develop world-class bonded storage and logistics facilities designed to serve the group’s five core end markets: sports, live entertainment, fine art, film & television, and luxury automotive. Once complete, Rock-It’s faci
L&T Technology Services Global EI Hackathon Sparks the Next Wave of AI-Native Engineering Solutions11.7.2026 13:35:00 CEST | Press release
Nearly 4,000 participants across 770+ teams from nine global locations became a part of the 24-hour innovation challenge L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services successfully concluded Engineering Intelligence (EI) OpenHack 2026, a first-of-its-kind global innovation challenge conducted simultaneously across nine locations spanning India, the U.S. and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260711573331/en/ LTTS Global EI OpenHack at the Munich office The hackathon brought together nearly 4,000 engineers (770+ teams) from Bengaluru, Mysuru, Chennai, Hyderabad, Pune, Vadodara, Mumbai, Dallas and Munich to tackle complex engineering challenges through AI-led innovation. More than 500 challenge statements were aligned with company’s strategic growth priorities, spanning Software Defined Mobility, Plant Buildout & Modernizati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
